Plecanatide + Linaclotide for Digestive Health
What You Need to Know Before You Apply
What is the purpose of this trial?
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken plecanatide, linaclotide, or similar GCC agonists in the past week, and you should not be using other investigational agents within 12 weeks prior to registration.
What safety data exists for Plecanatide and Linaclotide?
Plecanatide and Linaclotide are used for treating chronic idiopathic constipation and irritable bowel syndrome with constipation. Linaclotide has been evaluated in several clinical trials, showing it is generally well tolerated, with diarrhea being the most common adverse effect. About 10% of patients discontinued Linaclotide due to gastrointestinal side effects, primarily diarrhea. There is no relevant safety data for Linaclotide during pregnancy. Plecanatide's safety profile is not detailed in the provided research, but it is used for similar conditions as Linaclotide.12345
Is the drug Linaclotide, Plecanatide a promising treatment for digestive health?
What data supports the idea that Plecanatide + Linaclotide for Digestive Health is an effective drug?
The available research does not provide specific data on the effectiveness of Plecanatide + Linaclotide for Digestive Health. Instead, it focuses on other treatments for pancreatic conditions, such as pancreatic enzyme replacement therapy, which has shown improvements in symptoms like diarrhea and pain in patients with pancreatic cancer. Therefore, no direct comparison or data on Plecanatide + Linaclotide is available in the provided information.1112131415
Who Is on the Research Team?
David S. Weinberg
Principal Investigator
Fox Chase Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are not pregnant or breastfeeding, agree to use contraception, and have an ECOG performance status of <=1. They must be scheduled for an esophagogastroduodenoscopy (EGD), willing to provide biospecimens, and haven't used GCC agonists or investigational agents recently.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of plecanatide or linaclotide, or no drug, followed by standard of care EGD with biopsy and luminal fluid collection
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Linaclotide
- Plecanatide
Linaclotide is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
National Cancer Institute (NCI)
Collaborator